Magnus Hansson Email

Chief Medical Officer . Abliva AB

Current Roles

Employees:
17
Revenue:
$3.4M
About
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
Abliva AB Address
Medicon Village
Lund, null
Abliva AB Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.